Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 7, 2006, Pages 1342-1346

  Mizukami, Katsuyoshi ^a   Tanaka, Yoshiro ^b   Asada, Takashi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Ishizaki Hospital   (Japan)

Author keywords

Alzheimer's disease; Depression; Milnacipran; SNRI; SSRI

Indexed keywords

MILNACIPRAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MALE; REMISSION; SOMNOLENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CYCLOPROPANES; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747098193     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.03.004     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth ed. (1994.), American Psychiatric Association, Washington, D.C.
2. Briley M. Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol 13 (1998) 99-111
3. Folstein M.F., Folstein S., and McHugh P.R. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 12 (1975) 189-196
4. Gonzales-Salvdor T., Aragano C., Lyketsos C.G., and Barba A.C. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 14 (1999) 701-710
5. Gonzales-Salvdor T., Lyketsos C.G., Baker A.S., Roques C., Hovanek L., Steele C.D., et al. Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry 15 (2000) 181-189
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
7. Hindmarch I., Rigney U., and Briley M. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 49 (2000) 118-125
8. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. Br J Psychiatry 140 (1982) 566-572
9. Kimura M., Kanetani K., Imai R., Suzuki H., Isayama K., and Endo S. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. Int Clin Psychopharmacol 17 (2002) 121-125
10. Lyketsos C.G., DelCampo L., Steinberg M., Miles Q., Steele C.D., Munro C., et al. Treating depression in Alzheimer disease. Arch Gen Psychiatry 60 (2003) 737-746
11. Magai C., Kennedy G., Cohen C.I., and Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Geriatr Psychiatry 8 (2000) 66-74
12. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of health and human services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
13. Migliorelli R., Teson A., Sabe L., Petracchi M., Leiguarda R., and Starkstein S.E. Prevalence and correlates of dysthymia and major depression in Alzheimer's disease. Am J Psychiatry 152 (1994) 37-44
14. Morishia S., and Arita S. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Hum Psychopharmacol Clin Exp 18 (2003) 479-482
15. Morishita S., and Arita S. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol 19 (2004) 405-408
16. Moret C., Charveron J., Finberg J.P.M., Couzinier J.P., and Briley M. Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24 (1985) 1211-1219
17. Olin J.T., Katz I.R., Meyers B.S., Schneider L.S., and Lebowitz B.D. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 10 (2002) 129-141
18. Petracca G., Tesón A., Chemernski E., Leiguarda R., and Starkstein S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatr Clin Neurosci 8 (1996) 270-275
19. Petracca G., Chemernski E., and Starkstein S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 13 (2001) 233-240
20. Puech A., Montgomery S.A., Prost J.F., Solles A., and Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12 (1997) 99-108
21. Puozzo C., and Leonard B.E. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 Suppl.4 (1996) S15-S27
22. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 24 (1988) 653-659
23. Steele C., Rovner B., Chase G.A., and Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147 (1990) 1049-1051
24. Taragano F.E., Lyketsos C.G., Mangone C.A., Allegri R.F., and Comesaña-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38 (1997) 246-252
25. Teri L., Reifler B.V., Veith R.C., Barnes R., White E., Mclean P., et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 46 (1991) 372-377
26. Tignol J., Pujol-Domenech L., Chartres J.P., Léger J.-M., Plétan Y., Tonelli I., et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Arch Psychiatr Scand 97 (1988) 157-165
27. Zubenko G., Moossy J., and Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 47 (1990) 209-214